Magnetic graphene oxide increases the biocompatibility and nuclear factor erythroid 2-related factor 2 antioxidant of human cumulus cells: A lab-trial study.

OA: gold CC-BY-NC-4.0
AI-generated summary by qwen3.7-flash, 2026-09-07

This lab-trial study found that 50 µg/ml magnetic graphene oxide increased human cumulus cell viability and nuclear factor erythroid 2-related factor 2 antioxidant expression, potentially improving assisted reproductive technology outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by qwen3.7-flash, 2026-09-10 · read from full text

This laboratory trial investigated the effects of magnetic graphene oxide on human cumulus cells derived from women undergoing intracytoplasmic sperm injection for male factor infertility. The study found that specific concentrations of MGO significantly increased cell viability and reduced apoptosis while upregulating Nrf2 protein expression, indicating enhanced antioxidant defense mechanisms. These beneficial effects were dose- and time-dependent, with a safe activity window identified at 48 hours before toxicity emerged at higher doses. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BackgroundAlthough assisted reproductive technology has been improved, the success rate is only 30%. Since the interaction between oocytes and cumulus cells (CCs) is necessary for the formation of a fertile oocyte, increasing the survival rate of CCs can improve the function of oocytes in infertile women.ObjectiveThis study aimed to investigate the effects of magnetic graphene oxide (MGO) nanocomposite on the biocompatibility and antioxidant activity of human CCs.Materials and methodsIn this lab-trial study, from July 2021-2023 human CCs were collected from 37 women aged 20-37 yr and cultured in a medium containing Dulbecco's Modified Eagle's/F12, fetal bovine serum (10%), and penicillin-streptomycin (1%). Then CCs were treated with increasing concentrations of nano-MGO for 24, 48, and 72 hr (3[4, 5-dimethylthiazole-2-yl]-2, 5-diphenyltetrazolium bromide) assay and flow cytometry technique were used to compare the survival rate and apoptosis of CCs before and after treatment. Western blot test was used for expressing nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant in 2 groups.ResultsThe results of the present study showed that treatment with MGO increased the viability of CCs at a concentration of 50 µg/ml after 48 hr (p > 0.01). At higher doses (100 µg/ml) MGO decreased the survival rate of CCs (p > 0.05). Also, treatment with MGO at a concentration of 50 µg/ml increased the expression level of antioxidant protein Nrf2 in human CCs.ConclusionOur results highlight the use of MGO in a new strategy that improves CCs viability and secretion of antioxidant protein Nrf2, thereby potentially increasing in vitro fertilization outcomes.
Full text 18,441 characters · extracted from pmc-nxml · 2 sections · click to expand

Section

F. Kabiri: Data curation, writing-review, and editing. T. Foroutan: Conceptualization, investigation, methodology, project administration, supervision, visualization, writing-original draft, writing-review, and editing. M. Pashaiasl: Data curation and investigation.

Coi Statement

The authors declare that there is no conflict of interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00
unpaywall
last seen: 2026-05-21T05:10:58.409756+00:00
License: CC-BY-NC-4.0